University of Michigan Medical School, Ann Arbor, Michigan.
Department of Surgery, Michigan Medicine, Ann Arbor, Michigan.
Ann Surg. 2022 May 1;275(5):924-927. doi: 10.1097/SLA.0000000000004298. Epub 2020 Nov 12.
To determine if sleeve gastrectomy has weight-independent benefits on diabetes outcomes.
Weight loss is recommended when treating conditions such as diabetes, hypertension, and hyperlipidemia. Bariatric surgery has been shown to improve or resolve metabolic conditions, but weight loss outcomes vary by procedure type.
Using data from a statewide bariatric surgery registry, a total of 988 patients with a preoperative diagnosis of diabetes who underwent either laparoscopic sleeve gastrectomy (LSG) or laparoscopic adjustable gastric banding (LAGB) were included in the study. The patients were matched based on age, race, sex, preoperative body mass index (BMi) and weight loss at 1 year after surgery. Chi-square comparisons were conducted for medication discontinuation for diabetes. Secondary outcome measures included discontinuation of medications for hypertension and hyperlipidemia.
The mean age of patients was 53.9 years, 75.5% were female, 89.3% were White. Mean preoperative BMi was 44.8 kg/m2 and 75.7% had noninsulin dependent diabetes, whereas 24.3% had insulin dependent diabetes. Mean % BMi loss at 1 year is similar between the 2 groups (8.3% vs 8.1%, P = 0.3811). LSG patients had significantly higher rates of discontinuation of oral diabetes medication (70.4% vs 46.0%, P < 0.0001), insulin (51.7% vs 38.3%, P = 0.0341), anti-hypertensive (41.1% vs 26.0%, P < 0.0001), and cholesterol-lowering medications (40.1% vs 27.8%, P = 0.0016) when compared to LAGB patients.
Despite similar preoperative characteristics and postoperative weight loss, LSG patients experienced significantly higher rates of medication discontinuation for diabetes, hypertension, and hyperlipidemia than LAGB. These results suggest that LSG may have weight-independent effects on metabolic disease and should be considered in the treatment of diabetes, regardless of perceived weight loss outcomes.
确定胃袖状切除术是否对糖尿病治疗结果具有独立于体重的益处。
当治疗糖尿病、高血压和高血脂等疾病时,建议减轻体重。减重手术已被证明可以改善或解决代谢疾病,但手术类型不同,减重效果也不同。
利用全州范围的减重手术登记处的数据,共纳入 988 例术前诊断为糖尿病且接受腹腔镜袖状胃切除术(LSG)或腹腔镜可调胃束带术(LAGB)的患者。根据年龄、种族、性别、术前体重指数(BMI)和术后 1 年体重减轻情况对患者进行匹配。采用卡方检验比较糖尿病药物停药情况。次要结果指标包括高血压和高血脂药物停药情况。
患者平均年龄为 53.9 岁,75.5%为女性,89.3%为白人。术前平均 BMI 为 44.8kg/m2,75.7%为非胰岛素依赖型糖尿病,24.3%为胰岛素依赖型糖尿病。两组患者术后 1 年的 BMI 降低百分比相似(8.3%比 8.1%,P=0.3811)。LSG 患者的口服糖尿病药物停药率明显更高(70.4%比 46.0%,P<0.0001)、胰岛素(51.7%比 38.3%,P=0.0341)、抗高血压药物(41.1%比 26.0%,P<0.0001)和降胆固醇药物(40.1%比 27.8%,P=0.0016)。
尽管术前特征和术后减重相似,但与 LAGB 患者相比,LSG 患者的糖尿病、高血压和高血脂药物停药率明显更高。这些结果表明,LSG 可能对代谢疾病具有独立于体重的影响,无论预期的减重效果如何,都应考虑将其用于治疗糖尿病。